The U.S. Food and Drug Administration (FDA) has approved Blue Earth Diagnostics' F-18 rhPSMA-7.3 PET radiotracer for detecting prostate cancer.
F-18 rhPSMA-7.3 (Posluma) is indicated for men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence. The tracer is a radiohybrid agent consisting of a prostate-specific membrane antigen (PSMA) ligand that may be combined with isotopes such as F-18 for imaging purposes or lutetium-177 or actinium-225 for therapeutic use.
Posluma will be commercially available in early June 2023 and will become increasingly available nationally in coming months, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
